查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1830374

器官晶片市場（按材料、產品、技術、最終用戶、應用和器官類型）—2025-2032 年全球預測

Organs-on-chips Market by Material, Product, Technology, End User, Application, Organ Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，器官晶片市場規模將成長至 17.6249 億美元，複合年成長率為 35.25%。

主要市場統計數據
基準年2024年 1.5736億美元
預計2025年 2.1296億美元
預測年份：2032年 17.6249億美元
複合年成長率（%） 35.25%

簡要概述器官晶片的演變、相關人員的優先事項以及將微生理系統整合到轉化流程中的戰略要務

隨著器官晶片領域從學術上的好奇心逐漸發展成為一項能夠在體外更精確地重現人體生理學的關鍵技術，本介紹將該技術納入了研究機構和行業領導者的戰略議程。早期研究著重於可行性論證，而如今的重點已轉向可重複性、與標準化實驗室工作流程的整合以及與下游研發和轉換流程的兼容性。因此，開發者和採用者擴大評估平台，不僅關注其生物保真度，還關注其材料、可製造性和數據互通性。

玻璃、PDMS 和熱塑性塑膠等材料的選擇會影響設備的性能、可製造性和法規認可度，進而影響實驗室和商業團隊從原型製作到規模化生產的設計決策。耗材包括微孔盤和試劑等必需品，決定了每日實驗通量和成本結構。技術模式涵蓋微流體晶片（包括多層和單層晶片）到多器官和單器官晶片，從而支​​持從以器官為中心的研究到互聯系統級研究的廣泛應用。

最終用戶包括學術研究機構、生物技術公司、委外研發機構和製藥公司，後者包括全球性和專業性製藥公司，它們的風險接受度和採用時間表各不相同。常見應用包括疾病建模、高通量篩檢和先導藥物最適化的藥物發現、個人化醫療和毒性測試。目前正在開發的器官類型包括腸道、心臟、腎臟、使用肝細胞和球狀體策略的肝臟以及肺，每種器官類型都面臨各自的生物學、分析和監管挑戰。本引言透過強調優先事項的整合來構成執行摘要的其餘部分：生物學相關性、工業擴充性以及與現有研發工作流程的整合。

快速的技術成熟、模組化整合以及不斷變化的最終用戶期望如何重塑器官晶片創新的採用途徑和商業策略

器官晶片領域正在經歷一場變革性的轉變，其特點是技術日趨成熟、工作流程日趨整合，以及來自資助方和監管機構的期望不斷演變；這些變化正在再形成其應用路徑。如今，玻璃、PDMS 或熱塑性塑膠的選擇反映了生物相容性、光學透明度和生產擴充性之間的權衡取捨。因此，各公司正在重新評估其平台藍圖，優先考慮與自動化處理和成像系統的兼容性。

在產品策略方面，該行業正從孤立的儀器轉向整合解決方案，將微孔盤和試劑等耗材與可互通的儀器和軟體相結合，使最終用戶能夠以更少的內部工程開銷部署工作流程。多層和單層晶片的流體控制和製造成本各不相同，多器官晶片為系統級藥理學創造了機會，而單器官晶片則繼續在重點機制研究中發揮作用。這種技術多樣化伴隨著學術機構、生物技術公司、合約研究組織和製藥公司的深入參與（後者在全球製藥和專業製藥領域有不同的優先事項）。

應用領域正在同步擴充。雖然疾病建模和毒性測試仍然是核心，但藥物研發工作流程擴大納入針對器官特異性測量的高通量篩檢和先導化合物最佳化步驟。個人化醫療正在利用器官特異性環境中的患者來源先導化合物，例如腸道、心臟、腎臟、透過基於肝細胞和球狀體的肝臟系統進行的肝臟治療以及肺部治療，這重新引發了人們對捐贈多樣性、細胞來源和標準化方案的關注。總的來說，這些轉變強調了互通性、標準化和資料穩健性，這些標準將廣泛採用的平台與小眾的學術原型區分開來。

評估新推出的關稅政策對供應鏈、採購決策以及研發時間表在 2025 年前的累積營運和策略影響

2025年高關稅的實施迫使產業相關人員重新評估其供應鏈策略、採購時機以及零件和完整系統的地理採購決策，並將對整個價值鏈產生累積影響。許多設備製造商依賴專用組件，例如精密玻璃、PDMS和熱塑性塑膠等聚合物基板、微加工工具以及外包計量模組。由於關稅影響原料和次組件的進口，製造商面臨更高的到岸成本，這會影響定價、供應商選擇和庫存管理決策。因此，各團隊正在部署對沖策略，例如多方採購、增加本地庫存，以及在某些情況下將部分組裝業務遷移到更靠近關鍵客戶所在地的地方。

對於耗材（尤其是微孔盤和試劑），關稅環境增強了試劑本地化生產或跨司法管轄區授權多家供應商的獎勵，以避免單點故障。軟體和數位交付物受關稅的直接影響較小，但會因硬體出貨和整合測試延遲而受到連鎖反應。此外，依賴進口設備的合約研究組織和生物技術公司必須重新考慮計劃預算和進度，將採購交付前置作業時間、海關變化以及潛在的重新測試納入考量，以確保在重新採購組件時符合法規要求。

這些營運調整也影響著策略夥伴關係關係。為了減輕關稅的影響，企業越來越願意簽訂聯合生產協議、建立策略採購聯盟和區域分銷合作夥伴關係。例如，替代材料或替代品的認證可能會觸發額外的驗證要求，尤其是對於依賴肝細胞或球狀體系統的肝臟模型，這些系統必須證明其生物學性能。總而言之，關稅變化的累積影響正在導致供應鏈設計更加複雜，但也更具彈性，加速了關於近岸外包、供應商多元化以及與製造商和經銷商達成長期合約安排的討論。

詳細的細分分析揭示了材料、產品、技術、最終用戶、應用和器官特定選擇如何影響採用、檢驗和商業策略

特定細分市場的動態正在影響開發人員和買家對平台的優先排序，了解這些細微差別對於有效的產品組合管理至關重要。在玻璃、PDMS 和熱塑性塑膠之間進行材料選擇，不僅會影響裝置性能，還會影響其對高內涵成像的光學適用性和生產可擴展性。玻璃具有優異的光學性能和耐化學性，但製造過程可能較為複雜，而 PDMS 則因其快速原型製作和透氣滲透性而極具吸引力。

將產品細分為耗材、設備和軟體，可以揭示不同的利潤率、服務模式和客戶互動。耗材包括微孔盤和試劑，它們會產生經常性收益，並且需要強大的供應鏈連續性。在技​​術選擇方面，微流體晶片有多層和單層兩種類型，它們在控制複雜性和製造簡易性之間做出權衡；多器官晶片能夠實現與全身藥理學相關的新興表現型，而單器官晶片則支援有針對性的機制研究。

不同的最終用戶有不同的採用行為：學術研究機構優先考慮假設驅動研究的靈活性和成本效益；生物技術公司優先考慮概念驗證的速度和平台授權的可能性；委外研發機構優先考慮通量、可重複性和合規性；而製藥公司（無論是全球性公司還是專業性公司）則透過產品組合的一致性、降低監管風險以及加快候選藥物篩選的潛力來評估平台。應用驅動技術和營運需求。疾病建模和毒性測試需要生理保真度和檢驗的讀數；高通量篩檢和先導藥物最適化等藥物研發工作流程需要擴充性和自動化；個人化醫療依賴與患者來源細胞的兼容性。器官特異性細分（腸道、心臟、腎臟、採用肝細胞和球狀體策略的肝臟以及肺部）進一步決定了細胞來源、檢測方法開發和驗證途徑。整合這些細分視角，可以更精確地確定研發投資和商業性上市策略的優先順序。

製造能力、法規環境和研究生態系統的地理差異如何影響全球商業化和供應鏈策略

區域動態從根本上影響供應鏈的韌性、監管方式和夥伴關係策略，了解地域差異對於部署和商業化計畫至關重要。在美洲，製藥和生物技術中心的強勁需求正在推動早期商業化，鼓勵對本地組裝的投資以及與契約製造製造商的合作，以降低跨境關稅和運輸中斷帶來的風險。該地區的學術研究中心和新興企業持續為創新管道做出貢獻，圍繞生命科學投資的區域政策舉措正在鼓勵轉化合作，將設備開發人員與臨床和臨床前測試機構聯繫起來。

在歐洲、中東和非洲，監管協調工作和強大的委外研發機構系統為標準化驗證和合作研發計劃創造了有利環境。歐洲研究聯盟和專業製藥公司通常強調可重複性和遵守嚴格的安全框架，這體現在其材料選擇和設備合格策略中。有針對性的產學研合作以及對轉化能力建設的投資正在推動中東和非洲的早期應用。

亞太地區呈現出多元化的格局，擁有強大的製造能力、廣泛的熱塑性零件供應鏈以及顯著成長的生物技術新創公司。該地區強大的製造能力支持著耗材和設備的快速擴張，而領先的研究型大學和合約研究組織 (CRO) 則致力於推動藥物研發、疾病建模和毒性評估等應用情境的發展。這些地理差異意味著企業必須根據區域優勢自訂其商業化和夥伴關係模式，在接近性最終用戶與獲得專業供應商和監管途徑之間取得平衡。

透過消耗品、設備和軟體、檢驗的工作流程和可製造材料的垂直整合的策略價值來體現競爭和夥伴關係動態

隨著企業在設備工程、生物製藥整合和軟體分析方面的能力提升，器官晶片領域的競爭態勢正在不斷演變，策略差異化不再僅僅依賴單一技術優勢，而是更依賴生態系統的編配。成熟企業和創新新興企業都專注於垂直整合產品，將微孔盤和試劑等高品質耗材與強大的儀器和以數據為中心的軟體相結合，從而降低最終用戶的技術門檻，並創造持續的商機。

那些能夠針對疾病建模和毒性測試等關鍵應用展示檢驗的工作流程，並能夠客製化玻璃、PDMS 和熱塑性塑膠等可製造性設備材料的組織，將更有能力與合約研究組織和製藥公司建立戰略夥伴關係關係。同樣，那些能夠提供靈活微流體架構，並平衡多層和單層晶片功能以及多器官和單器官配置的技術領導者，能夠透過滿足高通量發現需求和深入的機制研究來創造價值。諸如生物模型授權、試劑供應合作以及投資支持標準化數據收集和分析的軟體平台等策略舉措，正在塑造競爭格​​局。

買方行為也青睞能夠支援各種終端用戶的供應商，從尋求經濟高效且適應性強的系統的學術機構，到需要嚴格驗證的全球製藥公司，再到對利基應用感興趣的專業製藥公司。投資於監管專業知識、可擴展生產以及支援長期專案的服務基礎設施的公司，更有可能提高客戶維繫，並在各個應用領域獲得更廣泛的應用。

為高階主管提供實用的策略和營運步驟，以加速採用、降低驗證風險並建立有彈性且可擴展的晶片器官經營模式

行業領導者應採取一系列切實可行的措施，將技術能力與商業性和營運韌性相結合。首先，優先考慮平衡生物性能和可製造性的材料策略，在開發週期早期對玻璃、PDMS 和熱塑性塑膠進行資格合格，以減少後期意外情況和檢驗負擔。其次，設計產品藍圖，將微孔盤和試劑等耗材與儀器和軟體整合，以創建無縫的工作流程。

第三，我們正在實現供應鏈多元化，並建立區域製造或組裝選項，以降低關稅相關風險和物流風險。同時，我們正在與主要供應商協商多年期合約，以確保關鍵耗材的連續性。第四，在技術開發中，我們保持模組化，以支援多層和單層晶片的變體，為多器官晶片整合提供途徑，使客戶能夠從單器官研究擴展到系統級研究，而無需更換整個平台。第五，我們優先考慮最終用戶的參與，為學術研究機構、生物技術公司、合約研發組織和製藥公司開發客製化產品，並為全球和專業製藥客戶提供量身定做的服務和檢驗套件。

最後，為了支援高通量篩檢和先導藥物最適化等藥物研發活動，以及疾病建模和個人化醫療應用，投資於能夠實現可重複性、實驗室間可比性以及與實驗室資訊系統整合的數據標準和軟體平台。這些措施結合，可以減少部署摩擦，並建立穩固的商業性地位。

採用嚴格的混合方法研究途徑，結合相關人員訪談、技術評估和區域供應鏈分析，為實際部署和夥伴關係決策提供資訊

本研究採用混合方法，結合定性產業訪談、技術文獻綜述以及設備架構和供應鏈路徑的比較分析，以確保科學、商業性和營運因素的平衡觀點。透過與學術機構、生物技術公司、合約研究組織和製藥公司的相關人員進行結構化訪談，收集了關鍵見解，提供了關於驗證標準、採購慣例以及與現有研發工作流程整合的挑戰的觀點。

技術評估檢視了玻璃、PDMS 和熱塑性塑膠之間的材料特性差異，並評估了製造選擇（例如多層晶片與單層晶片）如何影響可製造性和功能讀出。評估還採用了實驗室工作流程映射方法，以了解微孔盤和試劑等耗材如何與設備和軟體交互，用於疾病建模、透過高通量篩檢和先導藥物最適化進行藥物發現、個人化醫療和毒理學測試等應用。區域分析考慮了美洲、歐洲、中東和非洲以及亞太地區的製造能力、法律規範和生態系統成熟度，並重點關注了實際部署方面的考慮因素。

我們盡可能交叉引用公開的技術報告、專利態勢和平台檢驗案例研究，以確保可靠性。在整個過程中，我們專注於識別營運限制和應用障礙，而不是預測量化的市場軌跡，這使我們能夠為研發、商業和供應鏈領導者提供直接可行的建議。

關於技術嚴謹性、材料策略和供應鏈彈性如何決定器官晶片在研究和工業領域的應用速度和廣度的關鍵要點

總而言之，器官晶片正在從實驗平台轉變為實用工具，對藥物研發、毒性評估和個人化醫療途徑產生重大影響，前提是開發商和採購者在可重複性、材料策略和整合能力方面達成協議。材料選擇、設備架構和耗材生態系統之間的相互作用不僅會影響實驗結果，還會影響該解決方案在不同終端用戶中擴展和商業化的可行性。在開發早期解決供應鏈彈性和監管合格，將降低下游風險，並使合約研發機構和製藥合作夥伴能夠更可靠地採用該解決方案。

展望未來，那些提供經過驗證的可互通解決方案並投資於軟體和數據標準化的公司將能夠抓住疾病建模、高通量篩檢、先導藥物最適化活動以及腸道、心臟、腎臟、基於肝細胞和球體的肝臟和肺部器官特定用例方面的機會。透過將嚴謹的技術與切合實際的商業化和採購策略相結合，相關人員可以在管理營運複雜性的同時加速產生影響。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 整合多器官晶片用於綜合疾病建模和藥物反應分析
  • 採用誘導性多功能幹細胞模型在器官晶片平台中實現個人化醫療應用
  • 實施先進的微流體灌注系統，模擬組織晶片內的生理剪切應力和流體流動條件
  • 擴大高通量器官晶片篩檢平台，加速臨床前藥物發現與毒性測試
  • 開發血管化器官晶片模型，真實模擬屏障功能和內皮細胞相互作用
  • 利用器官晶片技術評估奈米藥物的傳遞和生物分佈，用於標靶治療
  • 將免疫系統組件整合到器官晶片設備中，以模擬發炎反應和免疫毒性評估
  • 器官晶片檢驗和商業化的法規結構和標準化工作的進展

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 器官晶片市場（依材料）

  • 玻璃
  • PDMS
  • 熱塑性塑膠

9. 器官晶片市場（依產品）

  • 耗材
    • 微孔盤
    • 試劑
  • 裝置
  • 軟體

第 10 章 器官晶片市場（依技術）

  • 微流體晶片
    • 多層晶片
    • 單層晶片
  • 多重器官晶片
  • 單一器官晶片

第 11 章 器官晶片市場（依最終用戶）

  • 學術機構
  • 生技公司
  • 合約研究組織
  • 製藥公司
    • 全球製藥公司
    • 專業製藥公司

第12章 器官晶片市場（依應用）

  • 疾病模型
  • 藥物研發
    • 高通量篩檢
    • 先導藥物最適化
  • 個人化醫療
  • 毒性測試

第13章 器官晶片市場（依器官類型）

  • 腸子
  • 心
  • 腎
  • 肝
    • 基於肝細胞
    • 球形底座
  • 肺

第14章器官晶片市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 15 章 器官晶片市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 器官晶片市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Emulate, Inc.
    • MIMETAS BV
    • TissUse GmbH
    • CN Bio Innovations Ltd.
    • InSphero AG
    • Nortis, Inc.
    • Hµrel Corporation
    • Tara Biosystems, Inc.
    • AxoSim LLC
    • Kirkstall Ltd
Product Code: MRR-431C35F6C22A

The Organs-on-chips Market is projected to grow by USD 1,762.49 million at a CAGR of 35.25% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 157.36 million
Estimated Year [2025] USD 212.96 million
Forecast Year [2032] USD 1,762.49 million
CAGR (%) 35.25%

A concise overview of organs-on-chips evolution, stakeholder priorities, and the strategic imperative for integrating microphysiological systems into translational pipelines

The organs-on-chips field has matured from academic curiosity to a pivotal technology enabling closer replication of human physiology outside the body, and this introduction situates the technology within the strategic agendas of research institutions and industry leaders. Early work focused on demonstrating feasibility; today emphasis has shifted toward reproducibility, integration with standardized laboratory workflows, and compatibility with downstream discovery and translational pipelines. As a result, developers and adopters increasingly evaluate platforms not only for biological fidelity but also for materials, manufacturability, and data interoperability.

Across laboratories and commercial teams, material choices such as Glass, PDMS, and Thermoplastics drive device performance, manufacturability, and regulatory acceptability, shaping design decisions from prototyping through scaled production. Concurrently, the product landscape spans Consumables, Instruments, and Software; consumables encompass essential items including Microplates and Reagents that determine day-to-day experiment throughput and cost structure. Technology modalities vary from Microfluidic Chips, which include both Multi Layer Chips and Single Layer Chips, to Multi Organ Chips and Single Organ Chips, enabling applications that range from focused organ studies to interconnected system-level investigations.

End users span Academic Institutes, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies, the latter of which includes both Global Pharma and Specialty Pharma entities with differing risk tolerances and adoption timelines. Common applications include Disease Modeling, Drug Discovery with High Throughput Screening and Lead Optimization activities, Personalized Medicine, and Toxicity Testing. Organ types addressed in current development efforts include Gut, Heart, Kidney, Liver with Hepatocyte Based and Spheroid Based strategies, and Lung, each presenting distinct biological, analytical, and regulatory challenges. This introduction frames the remainder of the executive summary by highlighting the converging priorities of biological relevance, industrial scalability, and integration into established R&D workflows.

How rapid technological maturation, modular integration, and changing end-user expectations are reshaping adoption pathways and commercial strategies in organ-on-chip innovation

The organs-on-chips landscape is undergoing transformative shifts characterized by technological maturation, consolidation of workflows, and evolving expectations from funders and regulators, and these changes are reshaping adoption pathways. New fabrication approaches and materials science innovations have reduced the gap between prototyping and manufacturable devices; the choice between Glass, PDMS, and Thermoplastics now reflects a deliberate trade-off among biological compatibility, optical clarity, and production scalability. As a result, organizations are re-evaluating platform roadmaps to prioritize compatibility with automated handling and imaging systems.

In product strategy, the industry is moving beyond siloed instruments toward integrated solutions that pair consumables such as Microplates and Reagents with interoperable Instruments and Software, enabling end users to deploy workflows with less in-house engineering overhead. The microfluidic technology base itself is diversifying; Multi Layer Chips and Single Layer Chips offer different fluidic control and fabrication cost profiles, while Multi Organ Chips create opportunities for system-level pharmacology and single organ chips retain roles in focused mechanistic studies. This technological diversification is accompanied by deeper engagement from Academic Institutes, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies, the latter with distinct priorities between Global Pharma and Specialty Pharma players.

Applications are broadening in parallel: Disease Modeling and Toxicity Testing remain core, while Drug Discovery workflows increasingly incorporate High Throughput Screening and Lead Optimization stages tailored to organ-specific readouts. Personalized Medicine initiatives are leveraging patient-derived cells in organ-specific contexts like Gut, Heart, Kidney, Liver with Hepatocyte Based and Spheroid Based liver systems, and Lung, driving renewed attention to donor variability, cell sourcing, and standardized protocols. These shifts collectively emphasize interoperability, standardization, and data robustness as the criteria that will separate widely adopted platforms from niche academic prototypes.

An assessment of the cumulative operational and strategic effects of newly implemented tariff policies on supply chains, sourcing decisions, and R&D timelines in 2025

The introduction of elevated tariff measures in 2025 has compelled industry participants to reassess supply chain strategies, procurement timing, and geographic sourcing decisions for components and finished systems, and these effects are cumulative across the value chain. Many device makers rely on specialized components, including precision glass, polymer substrates such as PDMS and thermoplastic resins, microfabrication tooling, and outsourced instrumentation modules. When tariffs affect imports of raw materials or subassemblies, manufacturers confront higher landed costs that influence decisions about pricing, vendor selection, and inventory management. Consequently, teams are deploying hedging strategies, including multi-sourcing, increased local stocking, and in some cases, partial relocation of assembly activities closer to key customer bases.

For consumables-Microplates and Reagents in particular-the tariff environment has amplified incentives to localize reagent production or to qualify multiple suppliers across jurisdictions to avoid single points of failure. Software and digital deliverables are less directly impacted by tariffs but encounter knock-on effects through delays in hardware shipments and integration testing, which in turn affect project timelines for instrument-based deployments. In addition, Contract Research Organizations and biotechnology firms that depend on imported instrumentation have had to revisit project budgets and timelines to incorporate procurement lead times, customs clearance variability, and potential retesting to ensure regulatory compliance when components are re-sourced.

These operational adjustments are also influencing strategic partnerships. Companies are increasingly open to co-manufacturing agreements, strategic sourcing alliances, and regional distribution partnerships to mitigate tariff exposure. Regulatory considerations intersect with trade policy; for example, qualification of alternative materials or substitutes may trigger additional validation requirements, particularly for liver models that depend on Hepatocyte Based or Spheroid Based systems where biological performance must be demonstrated. In sum, the cumulative impact of tariff changes has led to more resilient, albeit more complex, supply chain designs and has accelerated conversations about nearshoring, supplier diversification, and long-term contractual arrangements with manufacturers and distributors.

Detailed segmentation analysis revealing how material, product, technology, end-user, application, and organ-specific choices influence adoption, validation, and commercial strategy

Segment-specific dynamics shape how developers and purchasers prioritize platforms, and understanding these nuances is essential for effective portfolio management. Material choices among Glass, PDMS, and Thermoplastics influence not only device performance but also optical compatibility for high-content imaging and the feasibility of scaling production. Glass offers excellent optical properties and chemical resistance but can raise fabrication complexity; PDMS remains attractive for rapid prototyping and gas permeability, whereas Thermoplastics provide industrial manufacturability and lower per-unit costs when volumes justify tooling investments.

Product segmentation into Consumables, Instruments, and Software highlights differing margins, service models, and customer interactions. Consumables, which include Microplates and Reagents, generate recurring revenue and require robust supply chain continuity; Instruments demand higher upfront investment and are often paired with long-term service contracts; Software enables data standardization, analytics, and integration with laboratory information management systems, influencing stickiness and cross-sell potential. Within technology choices, Microfluidic Chips present both Multi Layer Chips and Single Layer Chips variants that trade off control complexity against ease of manufacture, while Multi Organ Chips enable emergent phenotypes relevant to systemic pharmacology and Single Organ Chips support targeted mechanistic studies.

End users exhibit distinct adoption behaviors: Academic Institutes prioritize flexibility and cost-effectiveness for hypothesis-driven research; Biotechnology Companies emphasize speed to proof-of-concept and potential for platform licensing; Contract Research Organizations focus on throughput, repeatability, and compliance; Pharmaceutical Companies, whether Global Pharma or Specialty Pharma, evaluate platforms through the lens of portfolio alignment, regulatory risk reduction, and potential to accelerate candidate selection. Applications drive technical and operational requirements: Disease Modeling and Toxicity Testing demand physiological fidelity and validated readouts, Drug Discovery workflows such as High Throughput Screening and Lead Optimization require scalability and automation, and Personalized Medicine depends on compatibility with patient-derived cells. Organ-specific considerations-Gut, Heart, Kidney, Liver with Hepatocyte Based and Spheroid Based strategies, and Lung-further determine cell sourcing, assay development, and validation pathways. Integrating these segmentation lenses enables more precise prioritization of R&D investment and commercial go-to-market tactics.

How geographic differences in manufacturing strength, regulatory environments, and research ecosystems shape commercialization and supply chain strategies globally

Regional dynamics fundamentally influence supply chain resilience, regulatory approaches, and partnership strategies, and understanding geographic variation is critical for deployment and commercialization plans. In the Americas, strong demand from established pharmaceutical and biotechnology hubs is driving early commercial uptake, supporting investments in localized assembly and partnerships with contract manufacturers to reduce exposure to cross-border tariffs and shipping disruptions. Academic research centers and startups in the region continue to contribute to innovation pipelines, and regional policy initiatives around life sciences investment are encouraging translational collaborations that connect device developers with clinical and preclinical testing sites.

In Europe, Middle East & Africa, regulatory harmonization efforts and a robust ecosystem of contract research organizations create an environment favorable to standardized validation and collaborative development projects. European research consortia and specialty pharma players often emphasize reproducibility and compliance with stringent safety frameworks, which inform material selection and device qualification strategies. Across the Middle East and Africa, nascent adoption is driven by targeted academic-industry partnerships and investments in translational capacity-building.

Asia-Pacific presents a diverse landscape, with strong manufacturing capabilities, extensive supply chains for thermoplastic components, and significant growth in biotechnology entrepreneurship. The region's manufacturing depth supports rapid scaling of consumables and instruments, while major research universities and CROs foster use cases in Drug Discovery, Disease Modeling, and toxicity assessment. These geographic differences mean that companies must tailor commercialization and partnership models to regional strengths, balancing proximity to end users with access to specialized suppliers and regulatory pathways.

Competitive and partnership dynamics driven by vertical integration of consumables, instrumentation, and software, and the strategic value of validated workflows and manufacturable materials

Competitive dynamics in the organs-on-chips domain are evolving as companies refine capabilities across device engineering, biologics integration, and software analytics, and strategic differentiation increasingly rests on ecosystem orchestration rather than single-technology advantage. Leading firms and innovative startups alike are focusing on vertically integrated offerings that combine high-quality consumables such as Microplates and Reagents with robust Instruments and data-centric Software, which together lower the technical entry barrier for end users and create recurring revenue opportunities.

Organizations that can demonstrate validated workflows for critical applications such as Disease Modeling and Toxicity Testing, and who can align device materials with manufacturability considerations spanning Glass, PDMS, and Thermoplastics, are better positioned to secure strategic partnerships with Contract Research Organizations and pharmaceutical partners. Similarly, technology leaders who offer flexible microfluidic architectures-balancing Multi Layer Chips and Single Layer Chips capabilities along with Multi Organ and Single Organ configurations-create value by addressing both high-throughput discovery requirements and detailed mechanistic studies. Strategic moves such as licensing biological models, forming reagent supply alliances, and investing in software platforms that enable standardized data capture and analytics are shaping the competitive landscape.

Buy-side behavior also favors providers that can support varied end users, from Academic Institutes seeking cost-effective, adaptable systems to Global Pharma requiring rigorous validation and Specialty Pharma interested in niche applications. Companies that invest in regulatory expertise, scalable manufacturing, and service infrastructures to support long-term programs will likely see higher customer retention and broader adoption across application domains.

Practical strategic and operational steps for executives to accelerate adoption, reduce validation risk, and build resilient, scalable organ-on-chip business models

Industry leaders should pursue a set of pragmatic, actionable measures that align technological capability with commercial and operational resilience, and these moves will accelerate adoption while managing execution risk. First, prioritize material strategies that balance biological performance and manufacturability by qualifying Glass, PDMS, and Thermoplastic options early in development cycles to reduce late-stage surprises and validation burdens. Second, design product roadmaps that integrate Consumables like Microplates and Reagents with Instruments and Software to create seamless workflows; bundling consumables with instruments can improve lifecycle economics and strengthen customer relationships.

Third, diversify supply chains and establish regional manufacturing or assembly options to mitigate tariff-related and logistical risks, while negotiating multi-year agreements with key suppliers to secure continuity for critical consumables. Fourth, in technology development, maintain modularity that supports both Multi Layer Chips and Single Layer Chips variants and offers pathways to Multi Organ Chips integration, so customers can scale from single-organ studies to system-level investigations without wholesale platform replacement. Fifth, prioritize end-user engagement by developing tailored offerings for Academic Institutes, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies, with distinct service and validation packages for Global Pharma and Specialty Pharma customers.

Finally, invest in data standards and software platforms that enable reproducibility, cross-lab comparability, and integration with laboratory information systems to support Drug Discovery activities such as High Throughput Screening and Lead Optimization, as well as Disease Modeling and Personalized Medicine applications. Taken together, these steps will reduce adoption friction and create defensible commercial positions.

A rigorous mixed-methods research approach combining stakeholder interviews, technical assessments, and regional supply chain analysis to inform practical deployment and partnership decisions

This research employed a mixed-methods approach that combined qualitative industry interviews, technical literature review, and comparative analysis of device architectures and supply chain pathways, ensuring a balanced view of scientific, commercial, and operational factors. Primary insights were gathered through structured interviews with stakeholders spanning Academic Institutes, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies, which provided perspectives on validation criteria, procurement practices, and integration challenges with existing R&D workflows.

Technical assessment examined differences in material properties among Glass, PDMS, and Thermoplastics and evaluated how fabrication choices such as Multi Layer Chips versus Single Layer Chips influence manufacturability and functional readouts. The methodology also included laboratory workflow mapping to understand how Consumables including Microplates and Reagents interface with Instruments and Software across applications like Disease Modeling, Drug Discovery with High Throughput Screening and Lead Optimization, Personalized Medicine, and Toxicity Testing. Regional analysis considered manufacturing capabilities, regulatory frameworks, and ecosystem maturity across the Americas, Europe, Middle East & Africa, and Asia-Pacific to highlight pragmatic deployment considerations.

Where possible, findings were triangulated against publicly available technical reports, patent landscapes, and case studies of platform validation to ensure reliability. Throughout the process, emphasis was placed on identifying operational constraints and adoption barriers rather than projecting quantitative market trajectories, enabling recommendations that are directly actionable for R&D, commercial, and supply chain leaders.

Key takeaways on how technical rigor, materials strategy, and supply chain resilience determine the pace and breadth of organs-on-chips adoption in research and industry

In conclusion, organs-on-chips are transitioning from experimental platforms to practical tools that can materially influence drug discovery, toxicity assessment, and personalized medicine pathways, provided developers and buyers align on reproducibility, materials strategy, and integration capabilities. The interplay between material selection, device architecture, and consumable ecosystems shapes not only experimental outcomes but also the feasibility of scaling and commercializing solutions across diverse end users. Addressing supply chain resilience and regulatory qualification early in development reduces downstream risk and enables more reliable adoption by Contract Research Organizations and pharmaceutical partners.

Looking forward, companies that deliver validated, interoperable solutions and invest in software and data standardization will capture opportunities across Disease Modeling, High Throughput Screening and Lead Optimization activities, and organ-specific use cases in Gut, Heart, Kidney, Liver with Hepatocyte Based and Spheroid Based systems, and Lung. By integrating technical rigor with pragmatic commercialization and sourcing strategies, stakeholders can accelerate impact while managing operational complexity.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of multi-organ chips for comprehensive disease modeling and drug response analysis
  • 5.2. Adoption of human-derived induced pluripotent stem cell models for personalized medicine applications in organ-on-chip platforms
  • 5.3. Implementation of advanced microfluidic perfusion systems to mimic physiological shear stress and fluid flow conditions in tissue chips
  • 5.4. Expansion of high-throughput organ-on-chip screening platforms for accelerated preclinical drug discovery and toxicity testing
  • 5.5. Development of vascularized organ-on-chip models to simulate realistic barrier functions and endothelial interactions
  • 5.6. Utilization of organ-on-chip technology for evaluating nanomedicine delivery and biodistribution in targeted therapies
  • 5.7. Incorporation of immune system components in organ-on-chip devices to recreate inflammatory responses and immunotoxicity assessments
  • 5.8. Regulatory framework advancements and standardization initiatives for organ-on-chip validation and commercialization

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Organs-on-chips Market, by Material

  • 8.1. Glass
  • 8.2. PDMS
  • 8.3. Thermoplastics

9. Organs-on-chips Market, by Product

  • 9.1. Consumables
    • 9.1.1. Microplates
    • 9.1.2. Reagents
  • 9.2. Instruments
  • 9.3. Software

10. Organs-on-chips Market, by Technology

  • 10.1. Microfluidic Chips
    • 10.1.1. Multi Layer Chips
    • 10.1.2. Single Layer Chips
  • 10.2. Multi Organ Chips
  • 10.3. Single Organ Chips

11. Organs-on-chips Market, by End User

  • 11.1. Academic Institutes
  • 11.2. Biotechnology Companies
  • 11.3. Contract Research Organizations
  • 11.4. Pharmaceutical Companies
    • 11.4.1. Global Pharma
    • 11.4.2. Specialty Pharma

12. Organs-on-chips Market, by Application

  • 12.1. Disease Modeling
  • 12.2. Drug Discovery
    • 12.2.1. High Throughput Screening
    • 12.2.2. Lead Optimization
  • 12.3. Personalized Medicine
  • 12.4. Toxicity Testing

13. Organs-on-chips Market, by Organ Type

  • 13.1. Gut
  • 13.2. Heart
  • 13.3. Kidney
  • 13.4. Liver
    • 13.4.1. Hepatocyte Based
    • 13.4.2. Spheroid Based
  • 13.5. Lung

14. Organs-on-chips Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Organs-on-chips Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Organs-on-chips Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Emulate, Inc.
    • 17.3.2. MIMETAS B.V.
    • 17.3.3. TissUse GmbH
    • 17.3.4. CN Bio Innovations Ltd.
    • 17.3.5. InSphero AG
    • 17.3.6. Nortis, Inc.
    • 17.3.7. Hµrel Corporation
    • 17.3.8. Tara Biosystems, Inc.
    • 17.3.9. AxoSim LLC
    • 17.3.10. Kirkstall Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. ORGANS-ON-CHIPS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. ORGANS-ON-CHIPS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ORGANS-ON-CHIPS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GLASS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GLASS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GLASS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GLASS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GLASS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GLASS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PDMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PDMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PDMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PDMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PDMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PDMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY THERMOPLASTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY THERMOPLASTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY THERMOPLASTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY THERMOPLASTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY THERMOPLASTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY THERMOPLASTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROPLATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROPLATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROPLATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROPLATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROPLATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROPLATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MULTI LAYER CHIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MULTI LAYER CHIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MULTI LAYER CHIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MULTI LAYER CHIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MULTI LAYER CHIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MULTI LAYER CHIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SINGLE LAYER CHIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SINGLE LAYER CHIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SINGLE LAYER CHIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SINGLE LAYER CHIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SINGLE LAYER CHIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SINGLE LAYER CHIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MULTI ORGAN CHIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MULTI ORGAN CHIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MULTI ORGAN CHIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MULTI ORGAN CHIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MULTI ORGAN CHIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY MULTI ORGAN CHIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SINGLE ORGAN CHIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SINGLE ORGAN CHIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SINGLE ORGAN CHIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SINGLE ORGAN CHIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SINGLE ORGAN CHIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SINGLE ORGAN CHIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GLOBAL PHARMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GLOBAL PHARMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GLOBAL PHARMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GLOBAL PHARMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GLOBAL PHARMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GLOBAL PHARMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SPECIALTY PHARMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SPECIALTY PHARMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SPECIALTY PHARMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SPECIALTY PHARMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SPECIALTY PHARMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SPECIALTY PHARMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DISEASE MODELING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DISEASE MODELING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DISEASE MODELING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DISEASE MODELING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DISEASE MODELING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DISEASE MODELING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY TOXICITY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY TOXICITY TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY TOXICITY TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY TOXICITY TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY TOXICITY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY TOXICITY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GUT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GUT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GUT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GUT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GUT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY GUT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HEART, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HEART, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HEART, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HEART, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HEART, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HEART, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY KIDNEY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY KIDNEY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY KIDNEY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY KIDNEY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY KIDNEY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY KIDNEY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HEPATOCYTE BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HEPATOCYTE BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HEPATOCYTE BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HEPATOCYTE BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HEPATOCYTE BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY HEPATOCYTE BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SPHEROID BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SPHEROID BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SPHEROID BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SPHEROID BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SPHEROID BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY SPHEROID BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LUNG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LUNG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LUNG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LUNG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY LUNG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ORGANS-ON-CHIPS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE, MIDDLE EAST & AFRICA ORGANS-ON-CHIPS MARKET SIZE, BY LIVER, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 323. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 324. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY MICROFLUIDIC CHIPS, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY DRUG DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 337. EUROPE ORGANS-ON-CHIPS MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 338. EUR